

**Consumer Healthcare Products Association (CHPA)  
PHENYLEPHRINE TASK GROUP**

**Efficacy Meta-Analysis of Single-Dose 10 mg Phenylephrine vs.  
Placebo in Adults With Acute Nasal Congestion Due to Common Cold**

*Final Report (January 30, 2007)*

**CHPA Phenylephrine Task Group** Heinz Schneider, Dr.Med.  
*Vice President, Regulatory & Scientific Affairs*  
Consumer Healthcare Products Association (CHPA)  
900 19<sup>th</sup> Street , NW, Suite 700, Washington, DC 20006  
Email: [hschneider@chpa-info.org](mailto:hschneider@chpa-info.org)

**Prepared By:** Christine Kollar, MS  
*Principal Statistician*  
GlaxoSmithKline Consumer Healthcare  
1500 Littleton Road, Parsippany, NJ 07054  
Email: [Christine.M.Kollar@gsk.com](mailto:Christine.M.Kollar@gsk.com)

Heinz Schneider, Dr.Med.  
CHPA, contact details see above

**Reviewed By:** Joel Waksman, PhD  
*Assistant Vice President, Biostatistics & Data Management*  
Wyeth Consumer Healthcare  
Five Giralda Farms, Madison, NJ 07940  
Email: [waksmaj@wyeth.com](mailto:waksmaj@wyeth.com)

Eva Krusinska, PhD  
*Director of Biostatistics and Data Management WW*  
GlaxoSmithKline Consumer Healthcare  
1500 Littleton Road, Parsippany, NJ 07054  
Email: [Eva.M.Krusinska@gsk.com](mailto:Eva.M.Krusinska@gsk.com)

**Report Date:** January 30, 2007

## TABLE OF CONTENTS

<b>1. BACKGROUND AND OBJECTIVES</b>	<b>5</b>
<b>2. STUDIES AVAILABLE FOR THE ANALYSES</b>	<b>6</b>
<b>3. STUDIES INCLUDED IN THE ANALYSES</b>	<b>8</b>
<b>4. STUDIES EXCLUDED FROM THE ANALYSES</b>	<b>10</b>
<b>5. METHODS</b>	<b>12</b>
<b>6. RESULTS</b>	<b>16</b>
<b>7. SUMMARY AND CONCLUSION</b>	<b>21</b>
<b>REFERENCES</b>	<b>22</b>
<b>FIGURES</b>	
Figure 1	<b>23</b>
Change from Baseline NAR: Treatment Difference (Phenylephrine minus Placebo) with 95% Confidence Limits By Study Assuming Patient is Random and for the Meta-Analysis Using Models 2.b and 3 -- 15 Minutes Post-Dose	
Figure 2	<b>24</b>
Change from Baseline NAR: Treatment Difference (Phenylephrine minus Placebo) with 95% Confidence Limits By Study Assuming Patient is Random and for the Meta-Analysis Using Models 2.b and 3 -- 30 Minutes Post-Dose	
Figure 3	<b>25</b>
Change from Baseline NAR: Treatment Difference (Phenylephrine minus Placebo) with 95% Confidence Limits By Study Assuming Patient is Random and for the Meta-Analysis Using Models 2.b and 3 -- 45 Minutes Post-Dose	
Figure 4	<b>26</b>
Change from Baseline NAR: Treatment Difference (Phenylephrine minus Placebo) with 95% Confidence Limits By Study Assuming Patient is Random and for the Meta-Analysis Using Models 2.b and 3 -- 60 Minutes Post-Dose	

Figure 5	27
Change from Baseline NAR: Treatment Difference (Phenylephrine minus Placebo) with 95% Confidence Limits By Study Assuming Patient is Random and for the Meta-Analysis Using Models 2.b and 3 -- 90 Minutes Post-Dose	
Figure 6	28
Change from Baseline NAR: Treatment Difference (Phenylephrine minus Placebo) with 95% Confidence Limits By Study Assuming Patient is Random and for the Meta-Analysis Using Models 2.b and 3 -- 120 Minutes Post-Dose	
Figure 7	29
Change from Baseline NAR: Treatment Difference (Phenylephrine minus Placebo) with 95% Confidence Limits By Study Assuming Patient is Random and for the Meta-Analysis Using Models 2.b and 3 -- 180 Minutes Post-Dose	
Figure 8	30
Change from Baseline NAR: Treatment Difference (Phenylephrine minus Placebo) with 95% Confidence Limits By Study Assuming Patient is Random and for the Meta-Analysis Using Models 2.b and 3 -- 240 Minutes Post-Dose	
Figure 9	31
% Change from Baseline by Study and Time (minutes) with 95% Confidence Limits for Each Treatment -- Patient is Random	
Figure 10	32
% Change from Baseline by Time (minutes) with 95% Confidence Limits for Each Treatment -- Model 2.a - Patient is Fixed	
Figure 11	33
% Change from Baseline by Time (minutes) with 95% Confidence Limits for Each Treatment -- Model 2.b - Patient is Random	
Figure 12	34
% Change from Baseline by Time (minutes) with 95% Confidence Limits for Each Treatment -- Model 3 - Patient, Study, and Treatment-by-study Interaction are Random	
Figure 13	35
LN-Ratio by Study and Time (minutes) with 95% Confidence Limits for Each Treatment -- Patient is Random; <i>LN-Ratio Has Been Back-transformed from the ln Scale to Base10 Scale</i>	
Figure 14	36
LN-Ratio by Time (minutes) with 95% Confidence Limits for Each Treatment -- Model 2.a - Patient is Fixed; <i>LN-Ratio Has Been Back-transformed from the ln Scale to the Base10 Scale</i>	
Figure 15	37
LN-Ratio by Time (minutes) with 95% Confidence Limits for Each Treatment -- Model 2.b -- Patient is Random; <i>LN-Ratio Has Been Back-transformed from the ln Scale to Base10 Scale</i>	
Figure 16	38
LN-Ratio by Time (minutes) with 95% Confidence Limits for Each Treatment -- Model 3 - Patient, Study, and Treatment-by-Study Interaction are Random; <i>LN-Ratio Has Been Back-transformed from the ln scale to the Base10 Scale</i>	

**List of Appendices** (which are available on request)

- Appendix 1    Technical Notes - SAS Version 8.2 Models
- Appendix 2    Phenylephrine vs. Placebo  
Change From Baseline NAR (Nasal Airflow Resistance) -- Performing Analysis of Covariance by Study and Time Point, Adjusting for Baseline NAR -- Patient Is Random
- Appendix 3    Meta-Analysis of Phenylephrine vs. Placebo  
Performing Analysis of Covariance by Time Point: Change from Baseline Nasal Airflow Resistance (NAR)
- Appendix 4.1    Meta-Analysis of Phenylephrine vs. Placebo  
Analysis of Change from Baseline Nasal Airflow Resistance and LN of Ratio (Post-baseline NAR/Baseline NAR) by Study and Time Point
- Appendix 4.2    Meta-Analysis of Phenylephrine vs. Placebo  
Analysis of Change from Baseline Nasal Airflow Resistance and LN of Ratio (Post-baseline NAR/Baseline NAR) by Model and Time Point
- Appendix 5    Meta-Analysis of Phenylephrine vs. Placebo  
Analysis of Change from Baseline Nasal Airflow Resistance and LN-Ratio (Post-baseline NAR/Baseline NAR) -- Standard Error of Treatment Response and Upper and Lower 95% Confidence Limits on Treatment Response by Time Point and Model